本帖最后由 老马 于 2013-3-13 13:43 编辑
& X9 ?5 Z _, i! S* y# B+ {
9 p+ h, T$ e: h6 n9 j健择（吉西他滨）+顺铂+阿瓦斯汀4 z1 {9 Q+ G$ K
Gemzar +Cisplatin + Avastin
9 A& X0 f( e' j9 I. W% uhttp://annonc.oxfordjournals.org/content/21/9/1804.full( e- p* A# J8 ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: J9 Z: o' T& u* Q3 R0 h$ uPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # u/ t( L" i& y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. * x: t( U. |+ {7 z/ g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 786)
: f) u: `. X8 H
华为网盘附件：, m* }& f1 D+ j# _3 D
【华为网盘】ava.JPG/ ?) i; w) Y. M* ]( q) u4 q
|
显身卡
